OR WAIT null SECS
September 18, 2021
"The promising rPFS and overall survival data support further evaluation of pembrolizumab plus olaparib in molecularly unselected patients with mCRPC who received prior docetaxel treatment,” the authors concluded.
The hard-to-treat subgroups consisted of age 65 years or older, presence of liver metastasis, primary upper tract disease, and nonresponse to prior PD-1/L1 inhibitor treatment.
Perioperative treatment with cabozantinib is feasible with early signs of clinical activity in patients with intermediate- and poor-risk metastatic renal cell carcinoma.
Investigators also found high concordance between the Guardant Health (360 or Omni) assays and FoundationOne CDx for the detection of BRCA and HRR mutations.
Additional prospective trials containing a larger sample size and longer follow up are needed to determine the optimal treatment sequence in favorable-risk advanced renal cell carcinoma.
The retrospective cohort study assessed outcomes in patients with advanced renal cell carcinoma who received cabozantinib or axitinib in the second-line setting or beyond.
The dual immunotherapy regimen maintained a survival benefit over single-agent sunitinib in patients with advanced renal cell carcinoma.
September 17, 2021
"Clinical benefit was observed regardless of homologous recombination repair gene mutational status," the study authors wrote.
The TKI/immunotherapy combination demonstrated strong clinical activity in patients with metastatic or locally advanced urothelial carcinoma (mUC) harboring FGFR alterations.
The findings come from an exploratory subgroup analysis of the pivotal CheckMate 9-ER trial shared during the 2021 ESMO Congress.
